Nivolumab Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Nivolumab Market Size Forecast: How Large Could The Market Become By 2030?
The nivolumab market has experienced a quick rate of expansion in recent years. Its value is projected to increase from $1.92 billion in 2025 to $2.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.9%. This historic growth has been driven by factors such as the growing incidence of melanoma and non-small cell lung cancer (NSCLC), the early regulatory approvals granted for nivolumab in treating metastatic cancers, the enhanced hospital infrastructure available for oncology care, the expansion of cancer research and clinical trial activities, and the broader uptake of monoclonal antibody therapies.
The projected size of the nivolumab market indicates swift expansion in the coming years. By 2030, it is anticipated to reach $3.63 billion, reflecting a compound annual growth rate (CAGR) of 13.8%. This upward trajectory during the forecast period is driven by factors such as the broadening of nivolumab’s approved indications, a growing number of elderly cancer patients, the incorporation of this drug into combination therapies, heightened financial commitments to biologics manufacturing, and the enhancement of oncology infrastructure in emerging markets. Key developments shaping this period include progress in immuno-oncology, the creation of novel combination treatments, the shift toward personalized cancer care, the growth of hospital-based oncology services, and the rising frequency of targeted therapeutic approaches.
Download A Free Sample Report For Comprehensive Market Insights:
Nivolumab Market Growth Momentum: Which Factors Are Influencing Demand?
The rising prevalence of non-small cell lung cancer (NSCLC) is anticipated to boost the Nivolumab market in the years ahead. NSCLC, a type of lung cancer originating in the epithelial cells of the lungs, is commonly treated with Nivolumab, an approved therapy for advanced cases. This drug’s effectiveness in addressing NSCLC drives its demand. For example, in March 2023, the American Society of Clinical Oncology, a US professional body representing oncologists across subspecialties, estimated that 238,340 individuals (117,550 men and 120,790 women) will be diagnosed with lung cancer in the United States, with NSCLC being the most prevalent type, accounting for 81% of all lung cancer diagnoses. Consequently, the growing incidence of NSCLC is fueling the expansion of the Nivolumab market.
The growing trend toward personalized medicine is set to propel the Nivolumab market forward. Personalized medicine involves customizing treatment and prevention strategies based on an individual’s unique genetic profile, lifestyle, and environmental factors, moving away from a universal approach. Its adoption is rising due to progress in genetic testing, which enables therapies to be adapted to specific patient characteristics. Nivolumab fits into this model by targeting particular immune pathways according to a patient’s tumor profile, offering more precise and effective cancer care. In February 2024, the Personalized Medicine Coalition, a US nonprofit organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a notable jump from the six approvals in 2022. Thus, the increasing embrace of personalized medicine is driving the growth of the Nivolumab market.
Nivolumab Market Segmentation And Category Breakdown
The nivolumab market covered in this report is segmented –
1) By Type: Injection 4mL, Injection 10mL
2) By Route Of Administration: Intravenous, Other Routes Of Administration
3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
4) By End-User: Clinic, Hospital, Other End-Users
Nivolumab Market Trends Reshaping Industry Growth
Key players in the nivolumab market are actively working on developing new formulations and broadening the range of treatable conditions to improve patient convenience and reinforce their immuno-oncology offerings. As an example, in December 2024, the Food and Drug Administration, a federal agency based in the United States, granted approval for Opdivo Qvantig, a subcutaneous version of nivolumab combined with hyaluronidase-nvhy, for all previously authorized adult solid-tumor indications where intravenous nivolumab was used. This new option can be administered as monotherapy, as maintenance therapy following Opdivo plus Yervoy, or alongside chemotherapy or cabozantinib. The approval was backed by the Phase 3 CHECKMATE-67T trial, which revealed comparable drug exposure, a similar safety profile, and a marginally higher response rate relative to IV nivolumab among patients with advanced renal cell carcinoma. Featuring flexible dosing schedules and sustained effectiveness, the subcutaneous formulation provides a more convenient choice for patients and bolsters Bristol Myers Squibb’s immuno-oncology pipeline.
Nivolumab Market Competitive Analysis Of Major Industry Participants
Major companies operating in the nivolumab market are Bristol-Myers Squibb Company, Ono Pharmaceutical Co. Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc., Dr. Reddy’s Laboratories Ltd., Biocon Limited, Samsung Bioepis Co. Ltd., Celltrion Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Intas Pharmaceuticals Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Zydus Lifesciences Limited, mAbxience, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., WuXi Biologics, Lonza Group AG, Samsung Biologics
Access The Complete Nivolumab Market Report:
Nivolumab Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the nivolumab market in 2025. The regions covered in the nivolumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
